Related coverage linked through entity extraction aliases.
Aug 07, 2026
Pilot genetic testing at ESMO Breast Cancer 2026 found inherited variants in 8.6% of breast and 10.1% of ovarian cancer survivors. A systematic review linked mammographic surveillance to a 50% lower mortality risk.
Jul 31, 2026
New studies reveal how cancer cells survive chemotherapy: fructose promotes ovarian cancer spread, platinum-treated 'zombie cells' release TGFβ in lung and ovarian cancers, and mitochondrial metabolism drives 5FU resistance in colorectal cancer. The findings point to potential combination therapy targets.
Aug 01, 2026
Preclinical studies reveal that fructose promotes metastasis in ovarian cancer by reducing cell adhesion, while brigatinib enhances PARP inhibitor efficacy by blocking an early adaptive resistance mechanism. The findings suggest dietary modifications and repurposing a lung cancer drug could improve outcomes for high-grade serous ovarian cancer patients.
Feb 14, 2026
Homologous recombination deficiency testing and molecular profiling are reshaping treatment strategies for advanced ovarian cancer, guiding PARP inhibitor and bevacizumab maintenance decisions in newly diagnosed patients.
